Abstract：
Probiotics exert beneficial effects by regulating the intestinal microbiota, metabolism, immune function and other ways of their host. Patients with constipation, a common gastrointestinal disorder, experience disturbances in their intestinal microbiota. In the present study, we investigated the effectiveness of two microbial ecological agents (postbiotic extract PE0401 and a combination of postbiotic extract PE0401 and Lacticaseibacillus paracasei CCFM 2711) in regulating the makeup of the intestinal microbiota and alleviating loperamide hydrochloride-induced constipation in mice. We also preliminarily explored the mechanism underlying their effects. Both microbial ecological agents increased the abundance of the beneficial bacteria Lactobacilli and Bifidobacterium after administration and were able to relieve constipation. However, the degree of improvement in constipation symptoms varied depending on the makeup of the supplement. The postbiotic extract PE0401 increased peristalsis time and improved faecal properties throughout the intestinal tract of the host. PE0401 relieved constipation, possibly by modulating the levels of the constipation-related gastrointestinal regulatory transmitters mouse motilin, mouse vasoactive intestinal peptide, and 5-hydoxytryptamine in the intestinal tract of the host and by increasing the levels of the short-chain fatty acids (SCFAs) acetic acid, propionic acid, and isovaleric acid. It also increased the relative abundance of Lactobacillus and Bifidobacterium and reduced that of Faecalibaculum, Mucispirillum, Staphylococcus, and Lachnoclostridium, which are among the beneficial microbiota in the host intestine. Furthermore, PE0401 decreased the levels of constipation-induced host inflammatory factors. Therefore, the two microbial ecological agents can regulate the intestinal microbiota of constipation mice, and PE0401 has a stronger ability to relieve constipation.
摘要：
益生菌通过调节肠道微生物群发挥有益作用，新陈代谢，免疫功能和宿主的其他方式。便秘患者,一种常见的胃肠道疾病，经历肠道微生物群的紊乱。在本研究中,我们研究了两种微生物生态制剂（后生物提取物PE0401和后生物提取物PE0401和副干酪乳杆菌CCFM2711的组合）在调节肠道微生物群组成和减轻盐酸洛哌丁胺诱导的小鼠便秘中的有效性。我们还初步探索了其作用的潜在机制。两种微生物生态制剂在给药后都增加了有益细菌乳杆菌和双歧杆菌的丰度，并且能够缓解便秘。然而,便秘症状的改善程度取决于补充剂的组成。后生物提取物PE0401增加了蠕动时间并改善了整个宿主肠道的粪便特性。PE0401缓解便秘，可能通过调节便秘相关的胃肠调节递质小鼠胃动素的水平，小鼠血管活性肠肽，和5-羟色胺在宿主的肠道和通过增加短链脂肪酸（SCFA）乙酸的水平，丙酸,和异戊酸。它还增加了乳杆菌和双歧杆菌的相对丰度，并降低了粪杆菌的相对丰度，Mucispirillum,葡萄球菌,和衣原体，它们是宿主肠道中有益的微生物群之一。此外，PE0401降低便秘诱导的宿主炎症因子水平。因此,这两种微生物生态制剂可以调节便秘小鼠的肠道菌群，和PE0401有更强的缓解便秘的能力。
